480 related articles for article (PubMed ID: 10392842)
1. Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease.
Hughes PE; Alexi T; Williams CE; Clark RG; Gluckman PD
Neuroscience; 1999; 92(1):197-209. PubMed ID: 10392842
[TBL] [Abstract][Full Text] [Related]
2. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of neurotrophin-4/5 and transforming growth factor-alpha on striatal neuronal phenotypic degeneration after excitotoxic lesioning with quinolinic acid.
Alexi T; Venero JL; Hefti F
Neuroscience; 1997 May; 78(1):73-86. PubMed ID: 9135090
[TBL] [Abstract][Full Text] [Related]
4. Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease.
Pérez-Navarro E; Akerud P; Marco S; Canals JM; Tolosa E; Arenas E; Alberch J
Neuroscience; 2000; 98(1):89-96. PubMed ID: 10858615
[TBL] [Abstract][Full Text] [Related]
5. Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA.
Venero JL; Beck KD; Hefti F
Neuroscience; 1994 Jul; 61(2):257-68. PubMed ID: 7969907
[TBL] [Abstract][Full Text] [Related]
6. Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease.
Huang Q; Zhou D; Sapp E; Aizawa H; Ge P; Bird ED; Vonsattel JP; DiFiglia M
Neuroscience; 1995 Mar; 65(2):397-407. PubMed ID: 7777157
[TBL] [Abstract][Full Text] [Related]
7. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease.
Kells AP; Fong DM; Dragunow M; During MJ; Young D; Connor B
Mol Ther; 2004 May; 9(5):682-8. PubMed ID: 15120329
[TBL] [Abstract][Full Text] [Related]
8. Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types.
Figueredo-Cardenas G; Harris CL; Anderson KD; Reiner A
Exp Neurol; 1998 Feb; 149(2):356-72. PubMed ID: 9500958
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease.
Emerich DF; Winn SR; Hantraye PM; Peschanski M; Chen EY; Chu Y; McDermott P; Baetge EE; Kordower JH
Nature; 1997 Mar; 386(6623):395-9. PubMed ID: 9121555
[TBL] [Abstract][Full Text] [Related]
10. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease.
Pérez-Navarro E; Canudas AM; Akerund P; Alberch J; Arenas E
J Neurochem; 2000 Nov; 75(5):2190-9. PubMed ID: 11183872
[TBL] [Abstract][Full Text] [Related]
11. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats.
Figueredo-Cardenas G; Anderson KD; Chen Q; Veenman CL; Reiner A
Exp Neurol; 1994 Sep; 129(1):37-56. PubMed ID: 7925841
[TBL] [Abstract][Full Text] [Related]
12. Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease.
Araujo DM; Hilt DC
Neuroscience; 1997 Dec; 81(4):1099-110. PubMed ID: 9330371
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity.
Liang ZQ; Wang XX; Wang Y; Chuang DM; DiFiglia M; Chase TN; Qin ZH
Neurobiol Dis; 2005 Nov; 20(2):562-73. PubMed ID: 15922606
[TBL] [Abstract][Full Text] [Related]
14. Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats.
Figueredo-Cardenas G; Chen Q; Reiner A
Exp Neurol; 1997 Aug; 146(2):444-57. PubMed ID: 9270055
[TBL] [Abstract][Full Text] [Related]
15. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
[TBL] [Abstract][Full Text] [Related]
16. Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: a detailed time course of the cellular and GABA(A) receptor changes.
Brickell KL; Nicholson LF; Waldvogel HJ; Faull RL
J Chem Neuroanat; 1999 Oct; 17(2):75-97. PubMed ID: 10585160
[TBL] [Abstract][Full Text] [Related]
17. Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.
Giampà C; DeMarch Z; D'Angelo V; Morello M; Martorana A; Sancesario G; Bernardi G; Fusco FR
Eur J Neurosci; 2006 Jan; 23(1):11-20. PubMed ID: 16420411
[TBL] [Abstract][Full Text] [Related]
18. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid.
Beal MF; Brouillet E; Jenkins BG; Ferrante RJ; Kowall NW; Miller JM; Storey E; Srivastava R; Rosen BR; Hyman BT
J Neurosci; 1993 Oct; 13(10):4181-92. PubMed ID: 7692009
[TBL] [Abstract][Full Text] [Related]
19. Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage.
Pérez-Navarro E; Arenas E; Reiriz J; Calvo N; Alberch J
Neuroscience; 1996 Nov; 75(2):345-52. PubMed ID: 8931001
[TBL] [Abstract][Full Text] [Related]
20. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.
Tattersfield AS; Croon RJ; Liu YW; Kells AP; Faull RL; Connor B
Neuroscience; 2004; 127(2):319-32. PubMed ID: 15262322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
